Cost-effectiveness of early versus standard antiretroviral therapy in HIV-infected adults in Haiti

PLoS Medicine

Volumn 8, Issue 9, 2011, Pages

  Koenig, Serena P ^a   Bang, Heejung ^b   Severe, Patrice ^c   Juste, Marc Antoine ^c   Ambroise, Alex ^c   Edwards, Alison ^b   Hippolyte, Jessica ^c   Fitzgerald, Daniel W ^b   McGreevy, Jolion ^c   Riviere, Cynthia ^c   Marcelin, Serge ^c   Secours, Rode ^c   Johnson, Warren D ^b   Pape, Jean W ^b,c   Schackman, Bruce R ^b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c Department of Adolescent Medicine   (Haïti)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; EFAVIRENZ; LAMIVUDINE PLUS ZIDOVUDINE;

ADULT; ANTIVIRAL THERAPY; ARTICLE; CAREGIVER; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; FOLLOW UP; HAITI; HEALTH CARE COST; HEALTH CARE QUALITY; HOSPITALIZATION COST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LABORATORY TEST; LIFE EXPECTANCY; MAJOR CLINICAL STUDY; MORTALITY; OUTPATIENT CARE; RADIOGRAPHY; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; STANDARD; WORKMAN COMPENSATION; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; DRUG ADMINISTRATION; ECONOMICS; FEMALE; HEALTH CARE DELIVERY; MALE; PRACTICE GUIDELINE;

ADULT; ANTI-RETROVIRAL AGENTS; CD4 LYMPHOCYTE COUNT; COST-BENEFIT ANALYSIS; DELIVERY OF HEALTH CARE; DRUG ADMINISTRATION SCHEDULE; FEMALE; GUIDELINES AS TOPIC; HAITI; HEALTH CARE COSTS; HIV INFECTIONS; HUMANS; LIFE EXPECTANCY; MALE; STANDARD OF CARE;

EID: 80053321286     PISSN: 15491277     EISSN: 15491676     Source Type: Journal    
DOI: 10.1371/journal.pmed.1001095     Document Type: Article

References (43)

1. World Health Organization (2009) Rapid advice: antiretroviral therapy for HIV infection in adults and adolescents. Available: http://www.who.int/hiv/pub/arv/advice/en/index.html. Accessed 14 May 2010.
2. Severe P, Jean Juste MA, Ambroise A, Eliacin L, Marchand C, et al. (2010) Early versus standard antiretroviral therapy for HIV-infected adults in Haiti. N Engl J Med 363: 257-265.
3. Emery S, Neuhaus JA, Phillips AN, Babiker A, Cohen CJ, et al. (2008) Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving ART at baseline in the SMART study. J Infect Dis 197: 1133-1144.
4. World Health Organization (2010) Towards universal access: scaling up priority HIV/AIDS interventions in the health sector- progress report 2010. Available: http://www.who.int/hiv/pub/2010progressreport/report/en/index.html. Accessed 4 March 2011.
5. Republique d'Haiti Programme National de Lutte contre le Sida (2010) Rapport de situation nationale à l' intention de l'UNGASS. Available: http://data.unaids.org/pub/Report/2010/haiti_2010_country_progress_report_fr.pdf. Accessed 14 May 2010.
6. UNAIDS (2010) AIDSinfo database. Available: http://www.aidsinfoonline.org/. Accessed 20 January 2010.
7. Koenig SP, Riviere C, Leger P, Severe P, Atwood S, et al. (2008) The cost of antiretroviral therapy in Haiti. Cost Eff Resour Alloc 6: 3.
8. Severe P, Leger P, Charles M, Noel F, Bonhomme G, et al. (2005) Antiretroviral therapy in a thousand patients with AIDS in Haiti. N Engl J Med 353: 2325-2334.
9. Oanda Corporation (2009) FX history: historical currency exchange rates. Available: http://www.oanda.com/currency/historical-rates. Accessed 14 May 2010.
10. World Health Organization (2009) Global price reporting mechanism. Available: http://apps.who.int/hiv/amds/price/hdd/index.aspx. Accessed 14 May 2010.
11. International Dispensary Association Foundation (2009) International Dispensary Association Foundation. Available: http://www.ida.nl/. Accessed 14 May 2010.
12. International Monetary Fund Western Hemisphere Department (2009) International Monetary Fund country report number 09/258. Available: http://www.imf.org/external/pubs/ft/scr/2009/cr09258.pdf. Accessed 14 May 2010.
13. Petrou S, Bischof M, Bennett C, Elbourne D, Field D, et al. (2006) Cost-effectiveness of neonatal extracorporeal membrane oxygenation based on 7-year results from the United Kingdom Collaborative ECMO Trial. Pediatrics 117: 1640-1649.
14. Glick H, Doshi J, Sonnad S, Polsky D, (2007) Economic evaluation in clinical trials Oxford Oxford University Press.
15. Zhao H, Bang H, Wang H, Pfeifer PE, (2007) On the equivalence of some medical cost estimators with censored data. Stat Med 26: 4520-4530.
16. Zhao H, Tian L, (2001) On estimating medical cost and incremental cost-effectiveness ratios with censored data. Biometrics 57: 1002-1008.
17. Huang Y, (2009) Cost analysis with censored data. Med Care 47: S115-119.
18. Tan-Torres Edejer T, Baltussen R, Adam T, Hutubessy R, Acharya A, et al.eds. (2003) Making choices in health: WHO guide to cost-effectiveness analysis Geneva WHO.
19. Petrou S, Gray A, (2011) Economic evaluation alongside randomized controlled trials: design, conduct, analysis, and reporting. BMJ 342: d15487.
20. Cairns J, (2001) Discounting in economic evaluation. In: Drummond MF, McGuire A, editors. Economic evaluation in health care New York Oxford University Press Inc pp. 236-255.
21. Briggs AH, Gray AM, (1999) Handling uncertainty in economic evaluations of healthcare interventions. BMJ 319: 635-638.
22. Fieller EC, (1954) Some problems in interval estimation. J R Stat Soc Series B Stat Methodol 16: 175-185.
23. Mugyenyi P, Walker AS, Hakim J, Munderi P, Gibb DM, et al. (2010) Routine versus clinically driven laboratory monitoring of HIV antiretroviral therapy in Africa (DART): a randomised non-inferiority trial. Lancet 375: 123-131.
24. Koenig Serena P, Schackman Bruce R, Riviere C, Leger P, Charles M, et al. (2010) Clinical impact and cost of monitoring for asymptomatic laboratory abnormalities among patients receiving antiretroviral therapy in a resource poor setting. Clin Infect Dis 51: 600-608.
25. World Health Organization (2010) Antiretroviral therapy for HIV infection in adults and adolescents recommendations for a public health approach 2010 revision Geneva WHO.
26. Hutubessy R, Baltussen R, Torres-Edejer TT, Evans DB, (2003) WHO-CHOICE: choosing interventions that are cost-effective. In: Murray CJL, Evans DB, editors. Health systems performance assessment: debates, methods and empiricism Geneva WHO Editions.
27. Walensky RP, Wolf LL, Wood R, Fofana MO, Freedberg KA, et al. (2009) When to start antiretroviral therapy in resource-limited settings. Ann Intern Med 151: 157-166.
28. Freedberg KA, Kumarasamy N, Losina E, Cecelia AJ, Scott CA, et al. (2007) Clinical impact and cost-effectiveness of antiretroviral therapy in India: starting criteria and second-line therapy. AIDS 21 (Suppl 4): S117-128.
29. International Monetary Fund (2009) World economic outlook database. Available: http://www.imf.org/external/pubs/ft/weo/2009/01/weodata/index.aspx. Accessed 14 May 2010.
30. Medicins Sans Frontieres (2010) Untangling the web of antiretroviral price reductions. Available: http://utw.msfaccess.org/. Accessed 20 January 2011.
31. Gras L, Kesselring AM, Griffin JT, van Sighem AI, Fraser C, et al. (2007) CD4 cell counts of 800 cells/mm3 or greater after 7 years of highly active antiretroviral therapy are feasible in most patients starting with 350 cells/mm3 or greater. J Acquir Immune Defic Syndr 45: 183-192.
32. Kitahata MM, Gange SJ, Abraham AG, Merriman B, Saag MS, et al. (2009) Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med 360: 1815-1826.
33. Sterne JA, May M, Costagliola D, de Wolf F, Phillips AN, et al. (2009) Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies. Lancet 373: 1352-1363.
34. Kelley CF, Kitchen CM, Hunt PW, Rodriguez B, Hecht FM, et al. (2009) Incomplete peripheral CD4+ cell count restoration in HIV-infected patients receiving long-term antiretroviral treatment. Clin Infect Dis 48: 787-794.
35. May M, Sterne JA, Sabin C, Costagliola D, Justice AC, et al. (2007) Prognosis of HIV-1-infected patients up to 5 years after initiation of HAART: collaborative analysis of prospective studies. AIDS 21: 1185-1197.
36. Robbins GK, Spritzler JG, Chan ES, Asmuth DM, Gandhi RT, et al. (2009) Incomplete reconstitution of T cell subsets on combination antiretroviral therapy in the AIDS Clinical Trials Group protocol 384. Clin Infect Dis 48: 350-361.
37. Castilla J, Del Romero J, Hernando V, Marincovich B, Garcia S, et al. (2005) Effectiveness of highly active antiretroviral therapy in reducing heterosexual transmission of HIV. J Acquir Immune Defic Syndr 40: 96-101.
38. Lima VD, Johnston K, Hogg RS, Levy AR, Harrigan PR, et al. (2008) Expanded access to highly active antiretroviral therapy: a potentially powerful strategy to curb the growth of the HIV epidemic. J Infect Dis 198: 59-67.
39. Ingle SM, May M, Uebel K, Timmerman V, Kotze E, et al. (2010) Outcomes in patients waiting for antiretroviral treatment in the Free State Province, South Africa: prospective linkage study. AIDS 24: 2717-2725.
40. Larson BA, Brennan A, McNamara L, Long L, Rosen S, et al. (2010) Early loss to follow up after enrolment in pre-ART care at a large public clinic in Johannesburg, South Africa. Trop Med Int Health 15 (Suppl 1): 43-47.
41. Drummond MF, Sculpher MJ, Torrance GW, O'Brien BJ, Stoddart GL, (2005) Methods for the economic evaluation of health care programs. 3rd edition Oxford Oxford University Press.
42. Loubiere S, el Filal KM, Sodqi M, Loundou A, Luchini S, et al. (2008) When to initiate highly active antiretroviral therapy in low-resource settings: the Moroccan experience. Antivir Ther 13: 241-251.
43. Badri M, Cleary S, Maartens G, Pitt J, Bekker LG, et al. (2006) When to initiate highly active antiretroviral therapy in sub-Saharan Africa? A South African cost-effectiveness study. Antivir Ther 11: 63-72.